Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06947993
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • GHZ339 — DRUG
    GHZ339 administered at dose A, B, C and D
  • Placebo — DRUG
    Matching placebo

Study Details

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Key Dates

Start date
May 16, 2025
Status verified
Dec 2025
Primary completion
Nov 27, 2028
Completion
Dec 22, 2028

Study Design

Enrollment
224 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GHZ339 Dose A
    Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2
  • Experimental: GHZ339 Dose B
    Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2
  • Experimental: GHZ339 Dose C
    Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2
  • Experimental: GHZ339 Dose D
    Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2
  • Placebo Comparator: Placebo
    Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2

Primary Outcome Measure

Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16 [ Time Frame: Baseline, Week 16 ]

Central Contacts

  • Novartis Pharmaceuticals
    1-888-669-6682
    [email protected]
  • Novartis Pharmaceuticals
    +41613241111

Locations (22)

FacilityCityStateZIPSite coordinators
Novartis Investigative SiteBirminghamAlabama35233-
Novartis Investigative SiteBirminghamAlabama35244-
Novartis Investigative SiteFort SmithArkansas72916-
Novartis Investigative SiteFountain ValleyCalifornia92708-
Novartis Investigative SiteLos AngelesCalifornia90056-
Novartis Investigative SiteSacramentoCalifornia95815-
Novartis Investigative SiteSanta AnaCalifornia92701-
Novartis Investigative SiteSanta MonicaCalifornia90404-
Novartis Investigative SiteWashington D.C.District of Columbia20060-
Novartis Investigative SiteMiamiFlorida33144-
Novartis Investigative SiteAtlantaGeorgia30342-
Novartis Investigative SiteMaconGeorgia31217-
Novartis Investigative SiteLouisvilleKentucky40241-
Novartis Investigative SiteBrightonMassachusetts02135-
Novartis Investigative SiteTroyMichigan48084-
Novartis Investigative SiteSaint JosephMissouri64506-
Novartis Investigative SiteBrooklynNew York11203-
Novartis Investigative SiteArlingtonTexas76011-
Novartis Investigative SiteCypressTexas77433-
Novartis Investigative SiteDallasTexas75235-9069-
Novartis Investigative SiteHoustonTexas77030-
Novartis Investigative SiteSan AntonioTexas78218-

Find similar trials in Birmingham, AL

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Novartis Investigative Site· Birmingham, ALNovartis Investigative Site· Fort Smith, ARNovartis Investigative Site· Fountain Valley, CANovartis Investigative Site· Los Angeles, CANovartis Investigative Site· Sacramento, CANovartis Investigative Site· Santa Ana, CA

Related Studies